Official websites use. Share sensitive information only on official, secure websites. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Staging and treatment of adult neuroblastoma has yet to be formalized.
We sought to determine the utility of the pediatric classification system in adults and determine the efficacy of different treatment modalities. Anderson Cancer Center from January to September , were reviewed. International neuroblastoma risk group INRG variables were abstracted. The primary outcome of interest was actuarial progression-free survival. Median age of pediatric patients was 5 years range 3β16 and 47 years range 18β82 for adult patients.
In the treatment of L1 disease, median PFS for adults treated with surgery and radiation was Median PFS in L2 adult patients was 5. Adult and pediatric patients with neuroblastoma achieve similar survival outcomes. INRG classification should be employed to stratify adult neuroblastoma patients and help select treatment.
Neuroblastoma arises from primitive sympathetic neural cells primarily in the adrenal medulla and also in the paraspinal sympathetic ganglia in the neck, chest, abdomen, or pelvis [ 1 ]. Because of the rarity of adult neuroblastoma, staging systems and risk assessment tools have been developed using primarily pediatric data [ 5 ].
Clinically relevant pediatric factors that influence survival in children include stage, age, histology, tumor grade, MYCN oncogene status, chromosome 11q status, and DNA ploidy. These factors are currently part of the international neuroblastoma risk assessment system [ 6 ].
